Latest Insider Transactions at Vir Biotechnology, Inc. (VIR)
This section provides a real-time view of insider transactions for Vir Biotechnology, Inc. (VIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vir Biotechnology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vir Biotechnology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
8,348
+24.98%
|
-
|
|
Jun 22
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,000,000
-3.75%
|
-
|
|
Jun 22
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
11,974
+25.0%
|
-
|
|
Jun 22
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
1,000,000
-3.75%
|
-
|
|
Jun 21
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.46%
|
$698,004
$46.38 P/Share
|
|
Jun 17
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-14.4%
|
$501,810
$43.95 P/Share
|
|
Jun 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.38%
|
$215,000
$43.67 P/Share
|
|
Jun 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.19%
|
$25,000
$5.17 P/Share
|
|
Jun 15
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.48%
|
$61,875
$45.29 P/Share
|
|
Jun 15
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.46%
|
$1,375
$1.53 P/Share
|
|
Jun 03
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-12.59%
|
$513,480
$44.56 P/Share
|
|
Jun 02
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.2%
|
$410,000
$41.83 P/Share
|
|
Jun 02
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.74%
|
$0
$0.86 P/Share
|
|
Jun 01
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.48%
|
$57,750
$42.51 P/Share
|
|
Jun 01
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.46%
|
$1,375
$1.53 P/Share
|
|
May 21
2021
|
Vicki L Sato Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+0.2%
|
-
|
|
May 21
2021
|
Jeffrey S. Hatfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+50.0%
|
-
|
|
May 21
2021
|
Robert J More Director |
SELL
Grant, award, or other acquisition
|
Direct |
3,374
-3.51%
|
-
|
|
May 21
2021
|
Janet Napolitano Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+50.0%
|
-
|
|
May 21
2021
|
Robert Nelsen Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+10.99%
|
-
|
|
May 21
2021
|
Dipchand Nishar Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+50.0%
|
-
|
|
May 21
2021
|
Robert J Perez Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+50.0%
|
-
|
|
May 21
2021
|
Saira Ramasastry Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+50.0%
|
-
|
|
May 21
2021
|
Phillip A Sharp Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+3.01%
|
-
|
|
May 21
2021
|
Charles Elliott Sigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,374
+50.0%
|
-
|
|
May 20
2021
|
Robert J More Director |
SELL
Open market or private sale
|
Direct |
11,670
-5.89%
|
$513,480
$44.17 P/Share
|
|
May 19
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.3%
|
$667,656
$44.16 P/Share
|
|
May 19
2021
|
Saira Ramasastry Director |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$430,000
$43.73 P/Share
|
|
May 19
2021
|
Saira Ramasastry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$120,000
$12.76 P/Share
|
|
May 18
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.48%
|
$61,875
$45.03 P/Share
|
|
May 18
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.46%
|
$1,375
$1.53 P/Share
|
|
May 04
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.48%
|
$63,250
$46.03 P/Share
|
|
May 04
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.46%
|
$1,375
$1.53 P/Share
|
|
Apr 27
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-7.93%
|
$387,100
$49.5 P/Share
|
|
Apr 27
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,900
+7.35%
|
$7,900
$1.53 P/Share
|
|
Apr 19
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-2.49%
|
$112,320
$48.0 P/Share
|
|
Apr 19
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+2.43%
|
$2,340
$1.53 P/Share
|
|
Apr 16
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+3.68%
|
$3,500
$1.53 P/Share
|
|
Apr 13
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
5,560
-5.93%
|
$239,080
$43.57 P/Share
|
|
Apr 13
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,560
+5.6%
|
$5,560
$1.53 P/Share
|
|
Apr 09
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+13.7%
|
$14,000
$1.53 P/Share
|
|
Apr 08
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
4,180
+20.02%
|
-
|
|
Apr 08
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.84%
|
-
|
|
Apr 08
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
5,989
+20.0%
|
-
|
|
Apr 08
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.84%
|
-
|
|
Apr 07
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
4,180
+25.03%
|
-
|
|
Apr 07
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.81%
|
-
|
|
Apr 07
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
5,989
+25.0%
|
-
|
|
Apr 07
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.81%
|
-
|
|
Apr 01
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-42.85%
|
$354,144
$51.4 P/Share
|